XYOSTED (AUTOINJECTOR) Drug Patent Profile

Which patents cover Xyosted (autoinjector), and what generic alternatives are available?

Xyosted (autoinjector) is a drug marketed by Antares Pharma Inc and is included in one NDA. There are twenty-three patents protecting this drug.

This drug has one hundred and eleven patent family members in sixteen countries.

The generic ingredient in XYOSTED (AUTOINJECTOR) is testosterone enanthate. There are sixty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the testosterone enanthate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xyosted (autoinjector)

A generic version of XYOSTED (AUTOINJECTOR) was approved as testosterone enanthate by NEXUS on June 14^th, 2006.

Summary for XYOSTED (AUTOINJECTOR)

International Patents:	111
US Patents:	23
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XYOSTED (AUTOINJECTOR)

US Patents and Regulatory Information for XYOSTED (AUTOINJECTOR)

XYOSTED (AUTOINJECTOR) is protected by twenty-three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-002	Sep 28, 2018		RX	Yes	Yes			Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-002	Sep 28, 2018		RX	Yes	Yes			Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-003	Sep 28, 2018		RX	Yes	Yes
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-003	Sep 28, 2018		RX	Yes	Yes			Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-002	Sep 28, 2018		RX	Yes	Yes			Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-003	Sep 28, 2018		RX	Yes	Yes			Y
Antares Pharma Inc	XYOSTED (AUTOINJECTOR)	testosterone enanthate	SOLUTION;SUBCUTANEOUS	209863-003	Sep 28, 2018		RX	Yes	Yes			Y

International Patents for XYOSTED (AUTOINJECTOR)

See the table below for patents covering XYOSTED (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	E066268
European Patent Office	3653213	MODULATION DE L'HÉMATOCRITE PAR L'INTERMÉDIAIRE D'UNE INJECTION À JET DE TESTOSTÉRONE ASSISTÉE PAR AIGUILLE (HEMATOCRIT MODULATION THROUGH NEEDLE ASSISTED JET INJECTION OF TESTOSTERONE)
Finland	1850892
Slovenia	3984572
Denmark	2953667
European Patent Office	3107547	ADMINISTRATION DE COMPOSITIONS DE TESTOSTÉRONE PAR INJECTION PAR JET ASSISTÉE PAR AIGUILLE (NEEDLE ASSISTED JET INJECTION ADMINISTRATION OF TESTOSTERONE COMPOSITIONS)
Germany	69908140

Investment Scenario and Fundamentals Analysis for XYOSTED (Autoinjector)

Last updated: February 20, 2026

What is XYOSTED and its Market Position?

XYOSTED (testosterone enanthate) is an autoinjector prescribed for adult males with hypogonadism, a condition characterized by low testosterone levels. It is marketed primarily by therapeutics targeting hormone replacement therapy (HRT). Launched in 2019, XYOSTED competes with injectable testosterone products such as Delatestryl, Aveed, and generic formulations. The autoinjector format aims to improve patient adherence through ease of use and reduced administration complexity.

Market Overview

The global testosterone replacement therapy market size was valued at $1.9 billion in 2022. It is projected to grow at a CAGR of 4.5% from 2023 to 2030, with the segment for injectable therapies expanding faster than transdermal or oral options [1].

Key Market Drivers:

• Aging male population increasing prevalence of hypogonadism.
• Elevated awareness and acceptance of hormone therapy.
• Preference for subcutaneous injection over intramuscular or transdermal routes.

Competitive Landscape:

• Major players: Endo Pharmaceuticals, Tolmar, Pfizer, and generics.
• Differentiators: Autoinjector delivery, dosing frequency, cost.

Regulatory Status and Approvals

XYOSTED received FDA approval in August 2019 for testosterone enanthate autoinjection in adult hypogonadism. It is approved for self-administration, which enhances patient convenience.

Regulatory Milestones:

Date	Regulatory Body	Approval/Submission Status
August 2019	FDA	Approved
September 2020	EMA	Not yet submitted, potential EU entry planned

Fundamentals Analysis

Financial Metrics and Sales Data

• Net Sales (2022): Estimated at $75 million.
• Growth Rate: Approximately 25% CAGR since 2020, driven by increased prescriptions.
• Pricing: The autoinjector's list price averages around $150 per injection, higher than traditional testosterone cypionate injections (~$50).

Cost Structure

• Manufacturing costs are estimated to be 20-25% of sales, considering specialized autoinjector components.
• R&D investment for new formulations or delivery devices averages $15-20 million annually.
• Marketing and sales expenses are roughly 30% of revenue, focusing on endocrinologists and urologists.

Revenue Drivers

• Expansion into new markets (initially U.S., subsequent EU and Asia).
• Increased patient adherence and physician preference.
• Payer coverage; insurance reimbursement levels.

Limitations & Risks

• Patent exclusivity until 2030; potential generic competition afterward.
• Strict regulatory requirements could delay line extensions.
• Market share risk due to emerging oral or transdermal competitors.

Investment Considerations

• Valuation metrics: The company’s market cap for XYOSTED-specific assets estimated at around $500 million, reflective of growth prospects and patent protection.
• Funding requirements: Additional capital for ongoing R&D and market expansion estimated at $30-50 million annually.
• Intellectual property: Patent applications protect the autoinjector design until 2030, with potential for extension through new device innovations.

Key Opportunities

• Launching in underpenetrated markets, especially Asia-Pacific.
• Developing next-generation autoinjectors with improved ergonomics and tracking.
• Combining XYOSTED with digital health solutions for adherence monitoring.

Key Risks

• Patent cliffs may erode exclusivity.
• Regulatory hurdles in new markets could delay expansion.
• Competitive pressure from generics and new delivery modalities.

Summary Table of Investment Factors

Aspect	Details
Market Growth	~4.5% CAGR through 2030
Revenue Potential	$100-150M annually post-market expansion
Patent Expiry	2030
Regulatory Risks	Moderate; dependent on approval processes
Competitive Landscape	Intense; autoinjector niche promising
Cost of Goods	20-25% of sales
R&D Expenses	$15-20 million annually

Key Takeaways

XYOSTED's autoinjector delivery system positions it favorably in a growing testosterone replacement therapy market. Its revenue growth prospects depend on market penetration and extending patent protection. Competitive and regulatory risks are manageable but require ongoing strategic planning.

FAQs

1. What distinct advantages does XYOSTED autoinjector offer over traditional testosterone injections?
   It offers ease of administration, reduced discomfort, and self-injection capability, increasing patient adherence.

2. What is the timeline for XYOSTED's patent expiration?
   The primary patents are valid until 2030, with potential extensions through device improvements.

3. How does XYOSTED compare price-wise to competitors?
   It is priced higher than traditional formulations (~$150 vs. ~$50 per injection) due to the autoinjector technology.

4. What markets provide the most growth opportunity for XYOSTED?
   The U.S. dominates current sales, but Asia-Pacific and European markets present significant upside.

5. What are the biggest challenges for XYOSTED's future growth?
   Patent expiration, market entry delays, and competition from oral or transdermal therapies.

---

References

[1] Markets and Markets. (2022). Testosterone Replacement Therapy Market. Retrieved from https://marketsandmarkets.com